Lab21 makes molecular diagnostics deal with US oncology research centre
This article was originally published in Clinica
Executive Summary
Lab21 has agreed to provide molecular diagnostic support services to the new Institute for Translational Oncology Research (ITOR) in Greenville, South Carolina. The centre is moving into the personalised cancer therapy sector and aims to translate lab research into practical applications for patients. It is part of the Greenville University Hospital System University Medical Center. Lab21 hopes the deal will help it identify and develop new biomarker panels through interactions with cancer physicians at ITOR. Last year, the Cambridge, UK-based firm set up a US subsidiary, Lab21 Inc, in Greenville (www.clinica.co.uk, 23 December 2009). It says the potential relationship with ITOR was one of the reasons it chose the site.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.